osteopenia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Postmenopausal women with normal bone mass: (1) Aged 50-70 years, menopause for more than 3 years, right-handed; (2) Able to understand the research content and cooperate to complete the research; (3) Subjects voluntarily participate in the research and sign the informed consent; (4) No contraindications for fMRI scanning; (5) No arrhythmia; (6) T-score > -1; (7) No serious underlying diseases including but not limited to systemic diseases such as heart, brain, liver and kidney. 2. Postmenopausal women with osteopenia: (1) Aged 50-70 years, menopause for more than 3 years, right-handed; (2) Able to understand the research content and cooperate to complete the research; (3) Subjects voluntarily participate in the research and sign the informed consent; (4) No contraindications for fMRI scanning; (5) No arrhythmia; (6) T-score -1; (7) No serious underlying diseases including but not limited to systemic diseases such as heart, brain, liver and kidney. 4. Middle-aged and elderly men with osteopenia: (1) Aged 50-70 years, right-handed; (2) Able to understand the research content and cooperate to complete the research; (3) Subjects voluntarily participate in the research and sign the informed consent; (4) No contraindications for fMRI scanning; (5) No arrhythmia; (6) T-score<-1; (7) No serious underlying diseases including but not limited to systemic diseases such as heart, brain, liver and kidney.
Exclusion criteria
Exclusion criteria: 1. There are implants or surgical treatment at the inspection site; 2. Inconvenient to move or extremely weak or mentally abnormal, unable to cooperate with the completion of the examination; 3. There is strenuous activity 24 hours before the examination; 4. There is a history of using tobacco, alcohol, tea, coffee, and energy drinks 24 hours before the inspection; 5. Abnormal body temperature or use of antipyretic and analgesic drugs within 3 days before the examination; 6. Use of drugs that affect heart rate variability, such as antihistamines, hypnotics, sedatives, opioids, metformin, etc., within 3 days before the examination; 7. The investigator believes that the patient has other conditions that are not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bone mineral density;heart rate variability;brain fMRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| questionnaire;biomarker of bone metabolism; | — |
Countries
China